Partikula Overview

  • Founded

  • 2013

Founded
  • Status

  • Out of Business

  • Latest Deal Type

  • Out of Business

Partikula General Information

Description

Developer of novel therapeutics designed to treat oncology and other diseases. The company's therapeutics utilize proprietary chemical engineering technologies to develop compounds that specifically and directly target mitochondria, from the outer mitochondrial membrane to the mitochondrial matrix and areas in between, enabling patients to fight off a large number of major diseases including cancer, neurodegenerative disease, cardiovascular and metabolic disease and a number of rare orphan diseases.

Contact Information

Website
www.partikula.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Primary Office
  • 15491 South West 12th Street
  • Suite 408
  • Sunrise, FL 33326
  • United States
+1 (954) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Partikula Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business 01-Apr-2018 00.000 Completed Out of Business
4. Debt - General 30-Jun-2016 00.000 Completed Startup
3. Debt - General 20-Nov-2015 00.000 Completed Startup
2. Early Stage VC (Series A) 02-Feb-2015 $5M $5.15M Completed Startup
1. Angel (individual) 25-Mar-2014 $150K $150K Completed Startup
To view Partikula’s complete valuation and funding history, request access »

Partikula Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of novel therapeutics designed to treat oncology and other diseases. The company's therapeutics utilize propri
Biotechnology
Sunrise, FL
00.000
00000000 00 00.000

000000

it esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt
0000000000000
Bala Cynwyd, PA
00 As of 0000
00000
000000000

000000

nim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis
000000000000000
Lund, Sweden
0 As of 0000
000.00
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Partikula Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Larimar Therapeutics Formerly VC-backed Bala Cynwyd, PA 00 00000 000000000
000000 Formerly VC-backed Lund, Sweden 0 000.00 000000000 000.00
You’re viewing 2 of 2 competitors. Get the full list »

Partikula Patents

  • 2

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 1

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

Partikula Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20180028647-A1 Modifications of therapeutic agents for enhanced delivery to target sites Granted 27-Jul-2016 000000000
US-10478492-B2 Modifications of therapeutic agents for enhanced delivery to target sites Active 27-Jul-2016 000000000

Partikula Executive Team (4)

Name Title Board Seat Contact Info
Shanta Dhar Ph.D Scientific Founder
Nagesh Kolishetti Ph.D Vice President of Chemistry and Chemical Development
Marc Lippman MD Chief Medical Officer
David Kolb Chief Executive Officer, Co-Founder & Board Member
To view Partikula’s complete executive team members history, request access »

Partikula Board Members (4)

Name Representing Role Since
David Kolb Self Chief Executive Officer, Co-Founder & Board Member 000 0000
You’re viewing 1 of 4 board members. Get the full list »

Ready to get started?

Request a free trial